Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,178
Out of 5,157 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $33.40 | +25.75% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $169.43 | +121.33% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $74.41 | +54.55% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $80.65 | +14.07% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $19.45 | -38.30% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $14.46 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $66.35 | +35.64% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $222.08 | +21.58% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $103.15 | -34.08% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $13.11 | +243.25% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $111.84 | +145.89% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $17.23 | +114.74% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $67.79 | -11.49% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $69.96 | -49.97% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $238.24 | -66.00% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $33.40
Upside: +25.75%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $169.43
Upside: +121.33%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $74.41
Upside: +54.55%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $80.65
Upside: +14.07%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $19.45
Upside: -38.30%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $14.46
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $66.35
Upside: +35.64%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $222.08
Upside: +21.58%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $103.15
Upside: -34.08%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $13.11
Upside: +243.25%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $111.84
Upside: +145.89%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $17.23
Upside: +114.74%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $67.79
Upside: -11.49%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $69.96
Upside: -49.97%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $238.24
Upside: -66.00%